Evaluation of Macrocytosis



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2009 Feb 1;79(3):203-208.

Macrocytosis, generally defined as a mean corpuscular volume greater than 100 fL, is frequently encountered when a complete blood count is performed. The most common etiologies are alcoholism, vitamin B12 and folate deficiencies, and medications. History and physical examination, vitamin B12 level, reticulocyte count, and a peripheral smear are helpful in delineating the underlying cause of macrocytosis. When the peripheral smear indicates megaloblastic anemia (demonstrated by macroovalocytes and hypersegmented neutrophils), vitamin B12 or folate deficiency is the most likely cause. When the peripheral smear is nonmegaloblastic, the reticulocyte count helps differentiate between drug or alcohol toxicity and hemolysis or hemorrhage. Of other possible etiologies, hypothyroidism, liver disease, and primary bone marrow dysplasias (including myelodysplasia and myeloproliferative disorders) are some of the more common causes.

Macrocytosis, defined as a mean corpuscular volume greater than 100 fL, occurs in approximately 3 percent of the general population.1 Debate persists about the upper limit of normal values of mean corpuscular volume. In a recent study, 7 percent of patients had a mean corpuscular volume greater than 96 fL, and 1.7 percent had a mean corpuscular volume greater than 100 fL.2 With the advent of automated complete blood cell counters and the increased use of certain medications, elevations in the mean corpuscular volume may be more commonly encountered. This article describes a strategy for the evaluation of patients with macrocytosis, as well as a brief discussion on treatment of vitamin B12 and folate deficiencies.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Obtain a vitamin B12 level for every patient with an elevated mean corpuscular volume.

C

1, 35, 19

Evaluate peripheral smear for megaloblastosis and perform a reticulocyte count in patients with suspected macrocytosis.

C

1, 35, 19

Order methylmalonic acid and homocysteine levels if vitamin B12 level is borderline low (i.e., 100 to 400 pg per mL [74 to 295 pmol per L]).

C

8

Oral vitamin B12 may be as effective as intramuscular therapy for vitamin B12 deficiency.

B

21

Obtain red blood cell folate level if other etiologies are not found (serum folate levels may be misleading).

C

25, 26


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Obtain a vitamin B12 level for every patient with an elevated mean corpuscular volume.

C

1, 35, 19

Evaluate peripheral smear for megaloblastosis and perform a reticulocyte count in patients with suspected macrocytosis.

C

1, 35, 19

Order methylmalonic acid and homocysteine levels if vitamin B12 level is borderline low (i.e., 100 to 400 pg per mL [74 to 295 pmol per L]).

C

8

Oral vitamin B12 may be as effective as intramuscular therapy for vitamin B12 deficiency.

B

21

Obtain red blood cell folate level if other etiologies are not found (serum folate levels may be misleading).

C

25, 26


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Causes of macrocytosis and their prevalence in different populations are shown in Table 1.1,35 Although it is associated with anemia, hypothyroidism is a more common cause in older persons than in other age groups. Results of a study in New York City indicated that medications for treating human immunodeficiency virus (HIV) infection have become a more prominent cause of macrocytosis. Alcoholism is the cause in as many as 80 percent of patients in some populations.6 Bone marrow biopsy was only performed in these studies when another cause could not be determined, and resulted in diagnosis in approximately one fourth of these remaining patients.1 In recent years, an association has been found between Helicobacter pylori infection and vitamin B12 deficiency.7

Table 1.

Prevalence of Major Causes of Macrocytosis in Studied Populations

Etiology Study population
Hospitalized patients in New York City 3 (%) Outpatients in Finland 1 (%) Finnish persons older than 75 years 4 (%) Finnish and American patients 5 (%)

Alcohol

26

65

15

36

B12 and/or folate deficiency

6

9

28

21

Medications

37*

3

2

11

Hypothyroidism

1

12

5

Bone marrow dysplasias

6

1

5

5

Liver disease (nonalcoholic)

6

2

6

Reticulocytosis

8

7

Miscellaneous

3

21

13

7

Not established

7

22

12


note: Etiologies listed from most to least common.

*— 13 percent from zidovudine (Retrovir).

Information from references1 and 3 through 5.

Table 1.   Prevalence of Major Causes of Macrocytosis in Studied Populations

View Table

Table 1.

Prevalence of Major Causes of Macrocytosis in Studied Populations

Etiology Study population
Hospitalized patients in New York City 3 (%) Outpatients in Finland 1 (%) Finnish persons older than 75 years 4 (%) Finnish and American patients 5 (%)

Alcohol

26

65

15

36

B12 and/or folate deficiency

6

9

28

21

Medications

37*

3

2

11

Hypothyroidism

1

12

5

Bone marrow dysplasias

6

1

5

5

Liver disease (nonalcoholic)

6

2

6

Reticulocytosis

8

7

Miscellaneous

3

21

13

7

Not established

7

22

12


note: Etiologies listed from most to least common.

*— 13 percent from zidovudine (Retrovir).

Information from references1 and 3 through 5.

Pathophysiology

The causes of macrocytosis can be broadly classified as megaloblastic and nonmegaloblastic (Table 2).1,35,716 Megaloblastic processes are characterized on the peripheral smear by macroovalocytes and hypersegmented neutrophils, which are absent in nonmegaloblastic macrocytic processes (Figure 1). Nonmegaloblastic processes have round macrocytes or macroreticulocytes (Figure 2). Because the mechanisms producing macrocytosis are not completely understood, the separation between megaloblastic and nonmegaloblastic causes is somewhat artificial. However, this concept remains useful for identifying the most predominant etiology for macrocytosis. For example, whereas the effect of alcohol is thought to be primarily a nonmegaloblastic process, in chronic alcoholism there may be concomitant vitamin B12 or folate deficiency. 17,18

Table 2.

Differential Diagnosis of Macrocytosis

Megaloblastic (involving vitamin B12 and/or folate deficiencies)

Atrophic gastritis

Enteral malabsorption

Human immunodeficiency virus treatments

Anticonvulsants (some cause folate depletion)

Primary bone marrow disorders

Nitrous oxide abuse

Inherited disorders

Nonmegaloblastic

Alcohol abuse

Medication side effects (see Table 3)

Myelodysplasia

Hypothyroidism

Liver disease

Hemolysis

Hemorrhage

Chronic obstructive pulmonary disease

Splenectomy

False elevations

Cold agglutinins

Hyperglycemia

Marked leukocytosis


note: Diagnoses listed from most to least common.

Information from references 1, 3 through 5, and 7 through 16.

Table 2.   Differential Diagnosis of Macrocytosis

View Table

Table 2.

Differential Diagnosis of Macrocytosis

Megaloblastic (involving vitamin B12 and/or folate deficiencies)

Atrophic gastritis

Enteral malabsorption

Human immunodeficiency virus treatments

Anticonvulsants (some cause folate depletion)

Primary bone marrow disorders

Nitrous oxide abuse

Inherited disorders

Nonmegaloblastic

Alcohol abuse

Medication side effects (see Table 3)

Myelodysplasia

Hypothyroidism

Liver disease

Hemolysis

Hemorrhage

Chronic obstructive pulmonary disease

Splenectomy

False elevations

Cold agglutinins

Hyperglycemia

Marked leukocytosis


note: Diagnoses listed from most to least common.

Information from references 1, 3 through 5, and 7 through 16.

Figure 1.

Megaloblastic anemia, with macroovalocytes (thin arrows) and hypersegmented neutrophils (thick arrow).

View Large


Figure 1.

Megaloblastic anemia, with macroovalocytes (thin arrows) and hypersegmented neutrophils (thick arrow).


Figure 1.

Megaloblastic anemia, with macroovalocytes (thin arrows) and hypersegmented neutrophils (thick arrow).

Figure 2.

Microangiopathic hemolytic anemia (nonmegaloblastic), with polychromatophilic macrocytes (thin arrows) and normally segmented neutrophils (thick arrow). Schistocytes (short arrows) typical of this particular disorder are also present.

View Large


Figure 2.

Microangiopathic hemolytic anemia (nonmegaloblastic), with polychromatophilic macrocytes (thin arrows) and normally segmented neutrophils (thick arrow). Schistocytes (short arrows) typical of this particular disorder are also present.


Figure 2.

Microangiopathic hemolytic anemia (nonmegaloblastic), with polychromatophilic macrocytes (thin arrows) and normally segmented neutrophils (thick arrow). Schistocytes (short arrows) typical of this particular disorder are also present.

In megaloblastic processes, erythrogenic precursors are larger than mature red blood cells (RBCs) because folate and vitamin B12 deficiencies result in defective RNA and DNA syntheses. Serum elevations in homocysteine and methylmalonic acid result from defective biochemical processes in folate and B12 deficiencies, and could be used to clarify the cause of megaloblastic anemia, although this is not yet standard clinical practice.8

Nonmegaloblastic processes develop from multiple mechanisms and have not been fully outlined. Macrocytosis can occur when there is increased RBC production secondary to peripheral blood cell destruction (i.e., hemolysis) or loss (i.e., hemorrhage), leading to a reticulocytosis. Reticulocytes are incompletely processed RBCs and, therefore, are slightly larger than the average RBC. The mechanisms by which the other diseases listed in Table 11,35 cause macrocytosis have not been fully explained.

Diagnostic Strategy

Once macrocytosis is identified, the history and physical examination help narrow the differential diagnosis. The presence of anemia, the degree of elevation of the mean corpuscular volume, and the patient’s overall health guide how aggressively the work-up progresses. At least some amount of investigation is warranted if the diagnosis is not readily apparent or if the patient is anemic (defined by the World Health Organization as a hemoglobin level less than 13 g per dL [130 g per L] in men and less than 12 g per dL [120 g per L] in women).9

The algorithm outlined in Figure 3 suggests a work-up for macrocytosis. Physicians should begin by ordering a peripheral smear, a reticulocyte count, and a vitamin B12 serum level for all patients with macrocytosis. It may be necessary to specifically order a reticulocyte index in some laboratories, which assesses if there is an adequate bone marrow response. Hemorrhage or hemolysis is the most likely cause if the reticulocyte count is elevated, but anemia recovery also causes an elevation in the reticulocyte count. Measures of vitamin B12 are a useful part of the initial work-up, because if vitamin B12 deficiency is present but undiagnosed, folate repletion will correct the megaloblastic anemia, but not the possible neuropathic changes that occur with B12 deficiency. 19

Evaluation of Macrocytic Anemia

Figure 3.

Algorithm for the evaluation of macrocytic anemia. (RBC = red blood cell; MMA = methylmalonic acid.)

View Large

Evaluation of Macrocytic Anemia


Figure 3.

Algorithm for the evaluation of macrocytic anemia. (RBC = red blood cell; MMA = methylmalonic acid.)

Evaluation of Macrocytic Anemia


Figure 3.

Algorithm for the evaluation of macrocytic anemia. (RBC = red blood cell; MMA = methylmalonic acid.)

Although uncommon, consider the possibility of spurious macrocytosis. This may be caused by cold agglutinins, hyperglycemia, or leukocytosis. Cold agglutinins cause the RBCs to clump, making them appear larger to the automatic counter.10 Hyperglycemic blood is more concentrated, and when it is diluted to measure the mean corpuscular volume, the cells swell more than usual, causing a false elevation.11 Increased turbidity of a sample with marked leukocytosis also can cause the machine to overestimate the cell size.12

When the history and physical examination, peripheral smear, B12 level, and reticulocyte count have not lead to an obvious diagnosis, consider a comprehensive metabolic panel to look for liver and kidney disease, thyroid-stimulating hormone for thyroid disorders, and methylmalonic acid and homocysteine levels to assess for vitamin B12 deficiency, despite a normal vitamin B12 level. If the cause remains elusive, consider again whether the degree of anemia or the patient’s overall health warrants referral to a hematologist for bone marrow biopsy, or search for rarer causes, keeping in mind that the most extensive work-up will result in a diagnosis in approximately 90 percent of patients.

Specific Causes of Macrocytosis

VITAMIN B12 DEFICIENCY

Vitamin B12 is absorbed by the ileum when it is bound by intrinsic factor, which is produced by the parietal cells of the gastric mucosa. In pernicious anemia, the loss of parietal cells leads to insufficient absorption of vitamin B12, which then leads to vitamin B12 deficiency over time. Pernicious anemia is most commonly caused by auto-immune atrophic gastritis, in which autoantibodies are directed against parietal cells and intrinsic factor. Less commonly, pernicious anemia can be caused by nonautoimmune gastritis secondary to H. pylori infections and Zollinger-Ellison syndrome.

Patients with vitamin B12 deficiency may describe paresthesias related to peripheral neuropathy, poor or strict vegan diet, lack of socioeconomic resources, bowel-related symptoms (including diarrhea), or a history of bowel surgery for weight loss. Findings on physical examination may include neurologic signs such as ataxia, decreased proprioception, and vibratory sensation. Patients may also have poor dentition or nonspecific oral stomatitis or glossitis.

Because pregnant women take folic acid routinely in prenatal vitamins, macrocytic anemia is much less common during pregnancy. Consider nitrous oxide abuse in at-risk populations, because nitrous oxide inactivates vitamin B12 through oxidation.13 Other uncommon causes include Diphyllobothrium latum (i.e., fish tapeworm) infection or inherited disorders of cobalamin metabolism, including Imerslund syndrome (a congenital vitamin B12 malabsorption associated with proteinuria). 20 Only 10 percent of persons with vitamin B12 deficiency are actually anemic.19

The normal range for serum measures of vitamin B12 varies among laboratories. If the vitamin B12 level s borderline low (i.e., 100 to 400 pg per mL [74 to 295 pmol per L]), methylmalonic acid and homocysteine levels should be ordered and, if elevated, may provide evidence of B12 deficiency.8 The Schilling test (i.e., measuring enteral absorption of vitamin B12) is not widely available at this time.

Oral therapy appears to be as effective as intramuscular therapy for the treatment of vitamin B12 deficiency. Relapse of pernicious anemia occurs at a mean interval of 65 months after cessation of treatment. It is important for patients to adhere to long-term therapy because the deficiency will recur if treatment is stopped, unless a reversible cause is identified.22

FOLATE DEFICIENCY

The history of folate deficiency may mimic the history of vitamin B12 deficiency in regard to poor nutritional intake or absorption. In addition, 35 percent of patients with alcoholism and macrocytic anemia are folate deficient, which can be caused by poor nutritional intake, malabsorption, hepatobiliary dysfunction, and possibly increased folate catabolism.18,23 Some medications that are used to treat seizure disorders, cancer, and autoimmune diseases can lead to folate deficiency. For example, methotrexate directly inhibits dihydrofolate reductase, which leads to a functional folate deficiency.14 Other medications that affect folate metabolism include 5-fluorouracil (Adrucil), hydroxyurea (Hydrea), pyrimethamine (Daraprim), trimethoprim/sulfamethoxazole (Bactrim, Septra), pentamidine (Pentam), and phenytoin (Dilantin).24 Medications can also affect folate absorption, including metformin (Glucophage) and cholestyramine (Questran). Supplementing with folate may be necessary when treating a patient with such medications.15

Serum folate levels are not useful because they fluctuate rapidly with dietary intake and are not cost effective.25 RBC folate levels more accurately correlate with folate stores and should be performed if folate deficiency is suspected.26 In differentiating the cause of megaloblastic anemia, a methylmalonic acid level that is within normal range also points toward a diagnosis of folate deficiency, especially if the serum vitamin B12 level is within the normal range. Note that homocysteine levels will be elevated with vitamin B12 and folate deficiencies.

HIV MEDICATIONS

Treatment of HIV with reverse transcriptase inhibitors (e.g., stavudine [Zerit], lamivudine [Epivir], zidovudine [Retrovir]) will cause macrocytosis because they interfere with DNA production, which may lead to megaloblastic changes. Most patients with HIV who are being treated with reverse transcriptase inhibitors will display macrocytosis without anemia. This indicates medication compliance by the patient, and no treatment is necessary.27  Table 3 lists other medications that may cause macrocytosis.28

Table 3.

Medications That May Cause Macrocytosis

Treatments for human immunodeficiency virus: reverse transcriptase inhibitors (e.g., stavudine [Zerit], lamivudine [Epivir], zidovudine [Retrovir])

Anticonvulsants (e.g., valproic acid [Depakote], phenytoin [Dilantin])

Folate antagonists (e.g., methotrexate)

Chemotherapeutics (e.g., alkylating agents, pyrimidine, purine inhibitors)

Trimethoprim/sulfamethoxazole (Bactrim, Septra)

Biguanides (e.g., metformin [Glucophage]), cholestyramine (Questran)


Information from reference 28.

Table 3.   Medications That May Cause Macrocytosis

View Table

Table 3.

Medications That May Cause Macrocytosis

Treatments for human immunodeficiency virus: reverse transcriptase inhibitors (e.g., stavudine [Zerit], lamivudine [Epivir], zidovudine [Retrovir])

Anticonvulsants (e.g., valproic acid [Depakote], phenytoin [Dilantin])

Folate antagonists (e.g., methotrexate)

Chemotherapeutics (e.g., alkylating agents, pyrimidine, purine inhibitors)

Trimethoprim/sulfamethoxazole (Bactrim, Septra)

Biguanides (e.g., metformin [Glucophage]), cholestyramine (Questran)


Information from reference 28.

RETICULOCYTOSIS (HEMOLYSIS OR HEMORRHAGE)

For the patient’s history, questions that are pertinent to evidence of blood loss, whether chronic or acute, can point to reticulocytosis. As part of the family history, physicians should ask about the presence of certain hematologic syndromes, including sickle cell disease, hereditary spherocytosis, and glucose-6-phosphate dehydrogenase deficiency. In persons who do distance running, hemolysis from constant foot pounding has infrequently been shown to cause macrocytosis.29 The physical examination may reveal hepatosplenomegaly in hemolysis or other physical manifestations of blood loss (e.g., conjunctiva, mucosal pallor). In further diagnostic testing, the peripheral smear will reveal evidence of hemolyzed RBCs (e.g., bite cells, helmet cells). Macrocytosis results from the marrow’s response to increased cell destruction or blood loss, with release of reticulocytes into the peripheral circulation. Treatment should be focused on the underlying cause of hemolysis or hemorrhage.

ALCOHOL ABUSE

The Michigan Alcoholism Screening test and obtaining γ-glutamyltransferase levels were found to be the two most sensitive tests for detecting alcohol abuse in patients with macrocytosis.6 Physical findings consistent with alcoholism include gynecomastia, caput medusae, and jaundice. Alcohol use more commonly causes macrocytosis through its toxic effect than through folate deficiency secondary to alcoholism. The mean corpuscular volume is generally less than 110 fL with chronic alcohol use. Abstinence from alcohol rapidly corrects the elevated mean corpuscular volume.18

BONE MARROW DYSFUNCTION

As noted above, myeloproliferative disorders (sometimes called refractory anemia) are a more common cause of macrocytosis and anemia among older persons than in younger populations. Although the peripheral smear may be suggestive, bone marrow biopsy is required to establish this diagnosis. Referral will likely be necessary for the work-up and management.

OTHER ETIOLOGIES

Medications, hypothyroidism, liver and renal disease, and chronic obstructive pulmonary disease are associated with less dramatic elevations in the mean corpuscular volume. Nonalcoholic liver disease and hypothyroidism account for a substantial portion of macrocytosis. Patient history and physical examination should include a history of these medical diseases. Splenectomy may cause macrocytosis because cells are not processed as thoroughly when the spleen is absent. Down syndrome also may be associated with reticulocytosis or myeloproliferative disorders.30 Treatment, if needed, can be directed at the underlying disorder.

The Authors

JOYCE KAFERLE, MD, is a clinical assistant professor in the Department of Family Medicine at the University of Michigan, Ann Arbor, and currently serves as the medical director of Dexter Family Medicine, Dexter, Mich. Dr. Kaferle received her medical degree from the Medical College of Ohio in Toledo, and completed a family medicine residency at the University of Michigan.

CHERYL E. STRZODA, MD, is a clinical lecturer in the Department of Family Medicine at the University of Michigan. Dr. Strzoda received her medical degree from the University of Illinois at Chicago College of Medicine, and completed a family medicine residency at the University of Michigan.

Author disclosure: Nothing to disclose.

Address correspondence to Joyce Kaferle, MD, University of Michigan, 9884 James Dr., Saline, MI 48176 (e-mail: jkaferle@umich.edu). Reprints are not available from the authors.

REFERENCES

1. Seppä K, Heinilä K, Sillanaukee P, Saarni M. Evaluation of macrocytosis by general practitioners. J Stud Alcohol. 1996;57(1):97–100.

2. Rumsey SE, Hokin B, Magin PJ, Pond D. Macrocytosis—an Australian general practice perspective. Aust Fam Physician. 2007;36(7):571–572.

3. Savage DG, Ogundipe A, Allen RH, Stabler SP, Lindenbaum J. Etiology and diagnostic evaluation of macrocytosis. Am J Med Sci. 2000;319(6):343–352.

4. Mahmoud MY, Lugon M, Anderson CC. Unexplained macrocytosis in elderly patients. Age Ageing. 1996;25(4):310–312.

5. Colon-Otero G, Menke D, Hook CC. A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. Med Clin North Am. 1992;76(3):581–597.

6. Seppä K, Laippala P, Saarni M. Macrocytosis as a consequence of alcohol abuse among patients in general practice. Alcohol Clin Exp Res. 1991;15(5):871–876.

7. Kaptan K, Beyan C, Ural AU, et al. Helicobacter pylori–is it a novel causative agent in Vitamin B12 deficiency? Arch Intern Med. 2000;160(9):1349–1353.

8. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med. 1994;96(3):239–246.

9. World Health Organization. Nutritional Anaemias: Report of a WHO Scientific Group. Geneva: World Health Organization; 1968.

10. Gloster ES, Strauss RA. More on spurious red blood cell parameters. Am J Clin Pathol. 1985;84(6):775–776.

11. van Duijnhoven HL, Treskes M. Marked interference of hyperglycemia in measurements of mean (red) cell volume by Technicon H analyzers. Clin Chem. 1996;42(1):76–80.

12. Francis DA, Francis JL, Roath OS. Improved assessment of haemoglobin and red cell indices in blood samples with high white cell counts. Med Lab Sci. 1985;42(3):285–286.

13. Miller MA, Martinez V, McCarthy R, Patel MM. Nitrous oxide “whippit” abuse presenting as clinical B12 deficiency and ataxia. Am J Emerg Med. 2004;22(2):124.

14. Waxman S, Metz J, Herbert V. Defective DNA synthesis in human megaloblastic bone marrow: effects of homocysteine and methionine. J Clin Invest. 1969;48(2):284–289.

15. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(2):CD000951.

16. Greer JP, Wintrobe MM. Wintrobe’s Clinical Hematology. 11th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2004.

17. Clemens MR, Kessler W, Schied HW, Schupmann A, Waller HD. Plasma and red cell lipids in alcoholics with macrocytosis. Clin Chim Acta. 1986;156(3):321–328.

18. Maruyama S, Hirayama C, Yamamoto S, et al. Red blood cell status in alcoholic and non-alcoholic liver disease. J Lab Clin Med. 2001;138(5):332–337.

19. Chui CH, Lau FY, Wong R, et al. Vitamin B12 deficiency—need for a new guideline. Nutrition. 2001;17(11–12):917–920.

20. Zimran A, Hershko C. The changing pattern of megaloblastic anemia: megaloblastic anemia in Israel. Am J Clin Nutr. 1983;37(5):855–861.

21. Butler CC, Vidal-Alaball J, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. Fam Pract. 2006;23(3):279–285.

22. Savage D, Lindenbaum J. Relapses after interruption of cyanocobalamin therapy in patients with pernicious anemia. Am J Med. 1983;74(5):765–772.

23. Suh JR, Herbig AK, Stover PJ. New perspectives on folate catabolism. Annu Rev Nutr. 2001;21:255–282.

24. Moran RG, Keyomarsi K. Biochemical rationale for the synergism of 5-fluorouracil and folinic acid. NCI Monogr. 1987;(5):159–163.

25. Robinson AR, Mladenovic J. Lack of clinical utility of folate levels in the evaluation of macrocytosis or anemia. Am J Med. 2001;110(2):88–90.

26. Phekoo K, Williams Y, Schey SA, Andrews VE, Dudley JM, Hoff-brand AV. Folate assays: serum or red cell? J R Coll Physicians Lond. 1997;31(3):291–295.

27. Geené D, Sudre P, Anwar D, Goehring C, Saaïdia A, Hirschel B. Causes of macrocytosis in HIV-infected patients not treated with zidovudine. Swiss HIV Cohort Study. J Infect. 2000;40(2):160–163.

28. DRUGDEX System, PDR Electronic Library. Thompson Micromedex. Greenwood Village, Co.; 1974–2007.

29. Dang CV. Runner’s anemia. JAMA. 2001;286(6):714–716.

30. Wachtel TJ, Pueschel SM. Macrocytosis in Down Syndrome. Am J Ment Retard. 1991;95(4):417–420.



Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article